1159 related articles for article (PubMed ID: 32928094)
41. Preparation of end-capped pH-sensitive mesoporous silica nanocarriers for on-demand drug delivery.
Moreira AF; Gaspar VM; Costa EC; de Melo-Diogo D; Machado P; Paquete CM; Correia IJ
Eur J Pharm Biopharm; 2014 Nov; 88(3):1012-25. PubMed ID: 25229810
[TBL] [Abstract][Full Text] [Related]
42. Stimuli-responsive mesoporous silica nanoparticles: A custom-tailored next generation approach in cargo delivery.
Salve R; Kumar P; Ngamcherdtrakul W; Gajbhiye V; Yantasee W
Mater Sci Eng C Mater Biol Appl; 2021 May; 124():112084. PubMed ID: 33947574
[TBL] [Abstract][Full Text] [Related]
43. Recent advances in mesoporous silica nanoparticles for antitumor therapy: our contribution.
Baeza A; Manzano M; Colilla M; Vallet-Regí M
Biomater Sci; 2016 May; 4(5):803-13. PubMed ID: 26902682
[TBL] [Abstract][Full Text] [Related]
44. Mesoporous silica nanoparticles in nanomedicine applications.
Manzano M; Vallet-Regí M
J Mater Sci Mater Med; 2018 May; 29(5):65. PubMed ID: 29737405
[TBL] [Abstract][Full Text] [Related]
45. Targeted and controlled drug delivery by multifunctional mesoporous silica nanoparticles with internal fluorescent conjugates and external polydopamine and graphene oxide layers.
Tran AV; Shim K; Vo Thi TT; Kook JK; An SSA; Lee SW
Acta Biomater; 2018 Jul; 74():397-413. PubMed ID: 29775731
[TBL] [Abstract][Full Text] [Related]
46. Polydopamine-based surface modification of mesoporous silica nanoparticles as pH-sensitive drug delivery vehicles for cancer therapy.
Chang D; Gao Y; Wang L; Liu G; Chen Y; Wang T; Tao W; Mei L; Huang L; Zeng X
J Colloid Interface Sci; 2016 Feb; 463():279-87. PubMed ID: 26550786
[TBL] [Abstract][Full Text] [Related]
47.
Kumar H; Pani B; Kumar J; Kumar P
Curr Pharm Biotechnol; 2023; 24(10):1297-1306. PubMed ID: 37254276
[TBL] [Abstract][Full Text] [Related]
48. Functionalized Mesoporous Silica Nanoparticles for Drug-Delivery to Multidrug-Resistant Cancer Cells.
Igaz N; Bélteky P; Kovács D; Papp C; Rónavári A; Szabó D; Gácser A; Kónya Z; Kiricsi M
Int J Nanomedicine; 2022; 17():3079-3096. PubMed ID: 35859731
[TBL] [Abstract][Full Text] [Related]
49. Mesoporous silica nanoparticles: facile surface functionalization and versatile biomedical applications in oncology.
Huang R; Shen YW; Guan YY; Jiang YX; Wu Y; Rahman K; Zhang LJ; Liu HJ; Luan X
Acta Biomater; 2020 Oct; 116():1-15. PubMed ID: 32911102
[TBL] [Abstract][Full Text] [Related]
50. Facile synthesis of organosilica-capped mesoporous silica nanocarriers with selective redox-triggered drug release properties for safe tumor chemotherapy.
Shen L; Pan S; Niu D; He J; Jia X; Hao J; Gu J; Zhao W; Li P; Li Y
Biomater Sci; 2019 Apr; 7(5):1825-1832. PubMed ID: 30892297
[TBL] [Abstract][Full Text] [Related]
51. Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery: an update.
Castillo RR; Lozano D; González B; Manzano M; Izquierdo-Barba I; Vallet-Regí M
Expert Opin Drug Deliv; 2019 Apr; 16(4):415-439. PubMed ID: 30897978
[TBL] [Abstract][Full Text] [Related]
52. Chemoresponsive smart mesoporous silica systems - An emerging paradigm for cancer therapy.
Murugan B; Krishnan UM
Int J Pharm; 2018 Dec; 553(1-2):310-326. PubMed ID: 30316004
[TBL] [Abstract][Full Text] [Related]
53. Folic acid modified lipid-bilayer coated mesoporous silica nanoparticles co-loading paclitaxel and tanshinone IIA for the treatment of acute promyelocytic leukemia.
Li Z; Zhang Y; Zhu C; Guo T; Xia Q; Hou X; Liu W; Feng N
Int J Pharm; 2020 Aug; 586():119576. PubMed ID: 32603839
[TBL] [Abstract][Full Text] [Related]
54. Sugar-decorated mesoporous silica nanoparticles as delivery vehicles for the poorly soluble drug celastrol enables targeted induction of apoptosis in cancer cells.
Niemelä E; Desai D; Nkizinkiko Y; Eriksson JE; Rosenholm JM
Eur J Pharm Biopharm; 2015 Oct; 96():11-21. PubMed ID: 26184689
[TBL] [Abstract][Full Text] [Related]
55. Mesoporous Silica Nanoparticles as a Prospective and Promising Approach for Drug Delivery and Biomedical Applications.
Pu X; Li J; Qiao P; Li M; Wang H; Zong L; Yuan Q; Duan S
Curr Cancer Drug Targets; 2019; 19(4):285-295. PubMed ID: 30520373
[TBL] [Abstract][Full Text] [Related]
56. Advances in Multicompartment Mesoporous Silica Micro/Nanoparticles for Theranostic Applications.
Liu J; Liu T; Pan J; Liu S; Lu GQM
Annu Rev Chem Biomol Eng; 2018 Jun; 9():389-411. PubMed ID: 29618224
[TBL] [Abstract][Full Text] [Related]
57. Advances in the Use of Multifunctional Mesoporous Silica Nanoparticles and Related Nanomaterials as Carriers for the Cancer Treatment.
Song C; Wang X; Wang Y; Yu H; Cui Y; Ma T
Curr Drug Metab; 2018; 19(2):131-141. PubMed ID: 28758578
[TBL] [Abstract][Full Text] [Related]
58. L-Dopa release from mesoporous silica nanoparticles engineered through the concept of drug-structure-directing agents for Parkinson's disease.
Morales V; McConnell J; Pérez-Garnes M; Almendro N; Sanz R; García-Muñoz RA
J Mater Chem B; 2021 May; 9(20):4178-4189. PubMed ID: 33989370
[TBL] [Abstract][Full Text] [Related]
59. Advances in Peptide Functionalization on Mesoporous Silica Nanoparticles for Controlled Drug Release.
Hu JJ; Xiao D; Zhang XZ
Small; 2016 Jul; 12(25):3344-59. PubMed ID: 27152737
[TBL] [Abstract][Full Text] [Related]
60. Multifunctional mesoporous silica nanoparticles for biomedical applications.
Xu B; Li S; Shi R; Liu H
Signal Transduct Target Ther; 2023 Nov; 8(1):435. PubMed ID: 37996406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
